Anzeige
Mehr »
Login
Sonntag, 12.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
JanOne – Smallcap über Nacht mit Milliardentransaktionen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0HG6G | ISIN: SE0000736415 | Ticker-Symbol: C5G
Frankfurt
10.05.24
08:18 Uhr
1,590 Euro
+0,004
+0,25 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
OREXO AB Chart 1 Jahr
5-Tage-Chart
OREXO AB 5-Tage-Chart
RealtimeGeldBriefZeit
1,5981,70010.05.
PR Newswire
211 Leser
Artikel bewerten:
(1)

Orexo announces that the condition for early redemption of its existing bonds has been fulfilled

UPPSALA, Sweden, April 2, 2024 /PRNewswire/ -- On March 13, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) announced that the Company intends to redeem early the Company's existing senior unsecured bonds with maturity in February 2025 (ISIN SE0015193958) (the "Existing Bonds").

The early redemption was conditional upon that settlement of the Company's issue of new senior secured social bonds with a tenor of four years has occurred, which is further described in the Company's press release on March 13, 2024. This condition has been fulfilled and the early redemption is therefore no longer conditional. Hence, the early redemption will occur on April 11, 2024, and the redemption amount will be paid to each person who is registered as owner of Existing Bonds in the debt register maintained by Euroclear Sweden at the end of business on April 4, 2024.

For further information on the early redemption, see the Company's press release on March 13, 2024, and the notice of early redemption which is available on the Company's website.

For further information please contact:

Nikolaj Sørensen, President and CEO
Fredrik Järrsten, EVP and CFO
Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
E-mail: ir@orexo.com

About Orexo

Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.

For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.

The information was sent for publication, through the agency of the contact person set out above, on April 2, 2024, at 1.15 pm CET.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/orexo/r/orexo-announces-that-the-condition-for-early-redemption-of-its-existing-bonds-has-been-fulfilled,c3955093

The following files are available for download:

https://mb.cision.com/Main/694/3955093/2706270.pdf

Orexo PR_The condition for early redemption of its existing bonds fulfilled April 2 2024

Cision View original content:https://www.prnewswire.co.uk/news-releases/orexo-announces-that-the-condition-for-early-redemption-of-its-existing-bonds-has-been-fulfilled-302105698.html

Lithium vs. Palladium - Ist das die Chance des Jahrzehnts?
Sichern Sie sich den kostenlosen PDF-Report! So können Sie vom Boom der Rohstoffe profitieren.
Hier klicken
© 2024 PR Newswire
Diesen Artikel auf Deutsch lesen
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.